Daiichi and Ranbaxy - Top 10 deals of 2008

FierceBiotech's top 10 deals of 2008 featuring Daiichi Sankyo's $4.6 billion acquisition of Ranbaxy stock.Who: Daiichi Sankyo
With: Ranbaxy
What: $4.6B stake

Summary: In June Japan's Daiichi Sankyo signed a deal that gave it a leg up in both emerging markets and the generic drug market. The company paid $4.6 billion for a majority stake in India's generics giant Ranbaxy. In addition to the emerging market and generic benefits, Daiichi gained access to Ranbaxy's affordable R&D and manufacturing facilities. Ranbaxy became a subsidiary of Daiichi but Malvinder Singh will remained CEO. The deal was a must for Daiichi, which announced in 2007 that it was aiming for 60 percent over the next three years.

Daiichi and Ranbaxy - Top 10 deals of 2008
Read more on

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.